Bristol-Myers Squibb (BMY: 19.95*, +0.03, +0.15%) is considering taking a minority stake in Elan, the Irish drugmaker that specializes in neurodegenerative diseases, an area of interest for Bristol, Reuters reported. Elan is also holding talks with a second unidentified company.
Sorry, but that's just recycling the same WSJ story from Friday AH. It's now old news. Bottom line is WSJ made a report they are in talks citing unnamed sources. Only UBS has come out with anything new since Friday's WSJ report which is that BMY claims not to be in discussions with ELN. One or neither of the stories is correct. But they can't both be true. Will be interesting to watch play out. Hard to add a position here, though.
No news has come out from credible sources saying otherwise. Major news sources continue to discuss eln push upwards on speculation that it is trying to sell a minority stake to Bristol-Meyers. That means something is positively in the making.